Skip to main
CLBT

CLBT Stock Forecast & Price Target

CLBT Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cellebrite DI is a highly innovative and well-positioned company, with a proven track record of serving law enforcement and intelligence agencies globally. Its expansion into the corporate and enterprise market presents new growth opportunities, and its strong financial performance and strategic partnerships bode well for future success. However, the company must navigate potential challenges, such as changes in government spending and shifts in public perception of law enforcement technology.

Bears say

Cellebrite DI is heavily reliant on the public sector, which accounts for 90% of its revenue. This exposes the company to risk from budget changes, delays in budget approvals, and government shutdowns. Additionally, competition in the digital forensics market is intense, and Cellebrite must continually enhance its capabilities to stay ahead. However, the company's long-term growth potential could be significant, as it addresses a large and growing market with its AI-powered solutions, has a strong customer base, and is expanding into the private sector. Cellebrite also faces risks related to foreign currency fluctuations, sales cycles, and possible breaches. While the company's current valuation may offer some insulation, a market correction could still negatively impact its stock price.

CLBT has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cellebrite DI Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cellebrite DI Ltd (CLBT) Forecast

Analysts have given CLBT a Strong Buy based on their latest research and market trends.

According to 5 analysts, CLBT has a Strong Buy consensus rating as of Jul 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cellebrite DI Ltd (CLBT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.